USO - Texas Oncology - San Antonio Trials

USO - Texas Oncology - San Antonio	Welcome, Profile Billing Logout

31 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sanborn, Rachel E

SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting

700

Europe, Japan, US, RoW

Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo

Eli Lilly and Company, AstraZeneca

Carcinoma, Non-Small-Cell Lung

05/29

02/32

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Terminated

sapanisertib, CB-228

Faeth Therapeutics

Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation

01/23

RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

160

Osimertinib, Tagrisso, Ramucirumab, Cyramza

Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company

Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer

09/25

10/25

NCT04364048: Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Terminated

Induction Durvalumab, IMFINZI, Chemotherapy, cisplatin, carboplatin, etoposide, pemetrexed, taxane, Radiation, Consolidation durvalumab

Rachel Sanborn, AstraZeneca, Providence Cancer Center, Earle A. Chiles Research Institute

Lung Cancer, Non-small Cell Carcinoma

06/23

02/24

KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC

Active, not recruiting

US, RoW

Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®

Effector Therapeutics, Medpace, Inc., ICON plc

Non-small Cell Lung Cancer

10/24

12/24

CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Active, not recruiting

Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex

Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center

Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor

12/25

12/26

BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting

244

Pembrolizumab

Greg Durm, MD, Merck Sharp & Dohme LLC

NSCLC, Stage I

04/26

04/29

NCT02422381: MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

1/2

MK-3475, Anti-PD-1, Pembrolizumab, Gemcitabine, Gemzar

Providence Health & Services, Merck Sharp & Dohme LLC, Providence Cancer Center, Earle A. Chiles Research Institute

Carcinoma, Non-Small-Cell Lung

01/19

08/24

NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed

1/2

ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro

Advaxis, Inc.

Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma

02/22

NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Recruiting

1/2

196

US, RoW

IPG7236

Nanjing Immunophage Biotech Co., Ltd

Safety Issues, Tolerability, Pharmacokinetics

09/25

12/25

HPN328-4001, NCT04471727: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/)

Recruiting

1/2

232

Gocatamig, HPN328, MK-6070, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo

Small-Cell Lung Cancer, Neuroendocrine Carcinoma

11/27

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting

1/2

1410

Canada, US, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer

12/25

07/26

REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

	Data from a trial for NSCLC
	Jan 2022 - Jan 2022: Data from a trial for NSCLC

Active, not recruiting

1/2

284

Europe, Japan, US, RoW

CLN-081, TAS6417; zipalertinib

Cullinan Therapeutics Inc.

Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

01/26

03/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

248

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

03/26

NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed

1/2

109

Europe, Japan, US, RoW

TAK-981, Pembrolizumab

Takeda, Takeda Development Center Americas, Inc.

Advanced or Metastatic Solid Tumors

10/24

Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Recruiting

1/2

quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ

Genprex, Inc.

Small Cell Lung Cancer Extensive Stage

02/26

08/27

KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting

1/2

333

INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2

Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC

Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma

02/26

05/26

KontRASt-01, NCT04699188 / 2020-004129-22: Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active, not recruiting

1/2

344

Europe, Canada, Japan, US, RoW

JDQ443, TNO155, tislelizumab

Novartis Pharmaceuticals

KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms

08/26

NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

Terminated

US, RoW

GNX102

GlycoNex, Inc.

Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm

07/23

NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Completed

agenT-797, Approved ICIs

MiNK Therapeutics

Tumor, Solid

01/24

NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Terminated

BBP-398 with nivolumab

Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb

Non Small Cell Lung Cancer, Solid Tumor

04/24

07/24

C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Active, not recruiting

499

Europe, US

Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1

Agenus Inc.

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer

01/25

12/27

KEYNOTE-E29, NCT05653882: A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors

Recruiting

552

etakafusp alfa (AB248), pembrolizumab, KEYTRUDA®

Asher Biotherapeutics, Inc., Merck Sharp & Dohme LLC

Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma

08/26

05/27

NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Terminated

160

INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda

Inhibrx Biosciences, Inc

Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma

10/24

NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting

270

PRTH-101, Pembrolizumab

Incendia Therapeutics

Advanced or Metastatic Solid Tumors

09/27

Herzberg, Benjamin

SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting

700

Europe, Japan, US, RoW

Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo

Eli Lilly and Company, AstraZeneca

Carcinoma, Non-Small-Cell Lung

05/29

02/32

IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting

180

Europe, US, RoW

IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan

IDEAYA Biosciences

Solid Tumor

12/26

03/27

NST-628, NCT06326411: A Study to Investigate the Safety and Efficacy of Oral Tablets in Subjects With Solid Tumors

Recruiting

230

US, RoW

NST-628

Nested Therapeutics, Inc

Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation

11/28

11/29

NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting

750

Europe, Japan, US, RoW

LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab

Eli Lilly and Company

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor

01/30

J5M-OX-JOXA, NCT06561685: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Recruiting

340

Japan, US

LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel

Eli Lilly and Company, Loxo Oncology, Inc.

Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

10/27

05/28

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sanborn, Rachel E

SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting

700

Europe, Japan, US, RoW

Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo

Eli Lilly and Company, AstraZeneca

Carcinoma, Non-Small-Cell Lung

05/29

02/32

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Terminated

sapanisertib, CB-228

Faeth Therapeutics

Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation

01/23

RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

160

Osimertinib, Tagrisso, Ramucirumab, Cyramza

Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company

Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer

09/25

10/25

NCT04364048: Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Terminated

Induction Durvalumab, IMFINZI, Chemotherapy, cisplatin, carboplatin, etoposide, pemetrexed, taxane, Radiation, Consolidation durvalumab

Rachel Sanborn, AstraZeneca, Providence Cancer Center, Earle A. Chiles Research Institute

Lung Cancer, Non-small Cell Carcinoma

06/23

02/24

KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC

Active, not recruiting

US, RoW

Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®

Effector Therapeutics, Medpace, Inc., ICON plc

Non-small Cell Lung Cancer

10/24

12/24

CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Active, not recruiting

Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex

Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center

Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor

12/25

12/26

BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting

244

Pembrolizumab

Greg Durm, MD, Merck Sharp & Dohme LLC

NSCLC, Stage I

04/26

04/29

NCT02422381: MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

1/2

MK-3475, Anti-PD-1, Pembrolizumab, Gemcitabine, Gemzar

Providence Health & Services, Merck Sharp & Dohme LLC, Providence Cancer Center, Earle A. Chiles Research Institute

Carcinoma, Non-Small-Cell Lung

01/19

08/24

NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed

1/2

ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro

Advaxis, Inc.

Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma

02/22

NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Recruiting

1/2

196

US, RoW

IPG7236

Nanjing Immunophage Biotech Co., Ltd

Safety Issues, Tolerability, Pharmacokinetics

09/25

12/25

HPN328-4001, NCT04471727: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/)

Recruiting

1/2

232

Gocatamig, HPN328, MK-6070, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo

Small-Cell Lung Cancer, Neuroendocrine Carcinoma

11/27

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting

1/2

1410

Canada, US, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer

12/25

07/26

REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

	Data from a trial for NSCLC
	Jan 2022 - Jan 2022: Data from a trial for NSCLC

Active, not recruiting

1/2

284

Europe, Japan, US, RoW

CLN-081, TAS6417; zipalertinib

Cullinan Therapeutics Inc.

Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

01/26

03/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

248

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

03/26

NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed

1/2

109

Europe, Japan, US, RoW

TAK-981, Pembrolizumab

Takeda, Takeda Development Center Americas, Inc.

Advanced or Metastatic Solid Tumors

10/24

Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Recruiting

1/2

quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ

Genprex, Inc.

Small Cell Lung Cancer Extensive Stage

02/26

08/27

KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting

1/2

333

Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC

Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma

02/26

05/26

KontRASt-01, NCT04699188 / 2020-004129-22: Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active, not recruiting

1/2

344

Europe, Canada, Japan, US, RoW

JDQ443, TNO155, tislelizumab

Novartis Pharmaceuticals

08/26

NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

Terminated

US, RoW

GNX102

GlycoNex, Inc.

Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm

07/23

NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Completed

agenT-797, Approved ICIs

MiNK Therapeutics

Tumor, Solid

01/24

NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Terminated

BBP-398 with nivolumab

Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb

Non Small Cell Lung Cancer, Solid Tumor

04/24

07/24

C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Active, not recruiting

499

Europe, US

Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1

Agenus Inc.

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer

01/25

12/27

KEYNOTE-E29, NCT05653882: A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors

Recruiting

552

etakafusp alfa (AB248), pembrolizumab, KEYTRUDA®

Asher Biotherapeutics, Inc., Merck Sharp & Dohme LLC

Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma

08/26

05/27

NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Terminated

160

INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda

Inhibrx Biosciences, Inc

10/24

NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting

270

PRTH-101, Pembrolizumab

Incendia Therapeutics

Advanced or Metastatic Solid Tumors

09/27

Herzberg, Benjamin

SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting

700

Europe, Japan, US, RoW

Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo

Eli Lilly and Company, AstraZeneca

Carcinoma, Non-Small-Cell Lung

05/29

02/32

IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting

180

Europe, US, RoW

IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan

IDEAYA Biosciences

Solid Tumor

12/26

03/27

NST-628, NCT06326411: A Study to Investigate the Safety and Efficacy of Oral Tablets in Subjects With Solid Tumors

Recruiting

230

US, RoW

NST-628

Nested Therapeutics, Inc

Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation

11/28

11/29

NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting

750

Europe, Japan, US, RoW

LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab

Eli Lilly and Company

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor

01/30

J5M-OX-JOXA, NCT06561685: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Recruiting

340

Japan, US

LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel

Eli Lilly and Company, Loxo Oncology, Inc.

Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

10/27

05/28

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites